TRAIL/Apo2L (tumour necrosis factor-related apoptosis-inducing ligand) has also been demonstrated to be important for IFNα-mediated growth inhibition and apoptosis in cancer cells such as melanoma, myeloma and hepatocellular carcinoma [11–13]. This evidence concerns the gene TNFSF10 and melanoma.